Century Therapeutics (NASDAQ:IPSC) Upgraded by Zacks Investment Research to Hold

Zacks Investment Research upgraded shares of Century Therapeutics (NASDAQ:IPSCGet Rating) from a sell rating to a hold rating in a research note published on Thursday morning, Zacks.com reports.

According to Zacks, “Century Therapeutics Inc. is a cell therapy company. It involved in developing induced pluripotent stem cell -derived cell therapies in immuno-oncology. Century Therapeutics Inc. is based in PHILADELPHIA. “

A number of other research firms have also weighed in on IPSC. Piper Sandler lowered their target price on Century Therapeutics from $38.00 to $22.00 and set an overweight rating for the company in a research note on Monday. William Blair began coverage on Century Therapeutics in a research note on Thursday, May 12th. They issued a market perform rating for the company. Finally, SVB Leerink reissued a buy rating and issued a $32.00 target price on shares of Century Therapeutics in a research note on Friday, March 18th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Century Therapeutics has an average rating of Buy and a consensus price target of $32.00.

IPSC opened at $8.40 on Thursday. Century Therapeutics has a 12-month low of $7.32 and a 12-month high of $32.90. The company has a current ratio of 16.62, a quick ratio of 14.57 and a debt-to-equity ratio of 0.03. The stock has a 50-day moving average price of $11.43 and a 200-day moving average price of $14.10.

Century Therapeutics (NASDAQ:IPSCGet Rating) last released its earnings results on Monday, May 16th. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.22). On average, research analysts anticipate that Century Therapeutics will post -2.38 earnings per share for the current fiscal year.

Several large investors have recently made changes to their positions in the company. Citigroup Inc. bought a new position in shares of Century Therapeutics in the 3rd quarter worth approximately $34,000. Royal Bank of Canada purchased a new stake in shares of Century Therapeutics in the 3rd quarter worth approximately $35,000. Goldman Sachs Group Inc. boosted its stake in Century Therapeutics by 11.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 20,746 shares of the company’s stock valued at $261,000 after purchasing an additional 2,091 shares during the last quarter. New York State Common Retirement Fund purchased a new stake in Century Therapeutics during the 3rd quarter valued at $53,000. Finally, American International Group Inc. boosted its stake in Century Therapeutics by 37.1% during the 1st quarter. American International Group Inc. now owns 8,604 shares of the company’s stock valued at $108,000 after purchasing an additional 2,328 shares during the last quarter. 57.50% of the stock is owned by hedge funds and other institutional investors.

About Century Therapeutics (Get Rating)

Century Therapeutics, Inc, a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma.

Recommended Stories

Get a free copy of the Zacks research report on Century Therapeutics (IPSC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Century Therapeutics (NASDAQ:IPSC)

Receive News & Ratings for Century Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Century Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.